Scale-up Cealus Health starts key study on microbiome product
June 28, 2021Amsterdam UMC scale-up company Caelus Health has reached an important milestone.
Caelus Health recently started a key clinical trial in individuals suffering from Metabolic Syndrome or pre-diabetes; these individuals are at risk of developing Type 2 diabetes.
The microbiome product based on a single micro-organism (named A. soehngenii) may delay or even prevent the onset of diabetes. The trial is a final step in the development and registration of this product as a food supplement following successful completion of the previous study.
Caelus Health was established in close cooperation with Wageningen University.
More news
Kick-off Biotech Booster programme in Amsterdam: Thematic Cluster 4 ‘Diagnostics/Services’
We’re off! As part of the Biotech Booster programme, IXA is setting up the Thematic Cluster 4 ‘Diagnostics/Services’ in Amsterdam.
News
Max Nijman (founder Flame Away) one of the 50 FD Talents
Only available in Dutch. Max Nijman, oprichter van VU startup Flame Away, is verkozen als een van de 50 talenten die verschijnen in het Financieel Dagblad 50 onder de 35. Dit is een lijst waarin gekeken wordt naar jonge talenten die de wereld een stukje beter maken. Max startte drie jaar geleden met een studieproject […]
News
Sign up for Amsterdam Science & Innovation Award 2023
Do you have an innovative idea that could positively impact tomorrow’s world?
Submit your idea and compete to win € 10,000!